Allogene Takes Step Closer To Off-The-Shelf CAR-Ts
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
You may also be interested in...
Former Kite exec David Chang is keen to use smaller firm's focus to advance allogeneic therapy more rapidly. The start-up acquired Pfizer R&D team along with its allogeneic CAR-T programs and related IP.
Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year.
The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda.